Current Therapies in Kidney Transplant Rejection
Journal of Clinical Medicine · 27.07.2023 · 12 (15) · 4927
DOI: 10.3390/jcm12154927 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.07.2023. Verfasst von Sami Alasfar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mayo Clinic, Phoenix, AZ 85054, USA. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite significant advancements in immunosuppressive therapies, kidney transplant rejection continues to pose a substantial challenge, impacting the long-term survival of grafts. This article provides an overview of the diagnosis, current therapies, and management strategies for acute T-cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR). TCMR is diagnosed through histological examination of kidney biopsy samples, which reveal the infiltration of mononuclear cells into the allograft tissue. Corticosteroids serve as the primary treatment for TCMR, while severe or steroid-resistant cases may require T-cell-depleting agents, like Thymoglobulin. ABMR occurs due to the binding of antibodies to graft endothelial cells. The most common treatment for ABMR is plasmapheresis, although its efficacy is still a subject of debate. Other current therapies, such as intravenous immunoglobulins, anti-CD20 antibodies, complement inhibitors, and proteasome inhibitors, are also utilized to varying degrees, but their efficacy remains questionable. Management decisions for ABMR depend on the timing of the rejection episode and the presence of chronic changes. In managing both TCMR and ABMR, it is crucial to optimize immunosuppression and address adherence. However, further research is needed to explore newer therapeutics and evaluate their efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.
- Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Zitieren
APA
Alasfar, S., Kodali, L., & Schinstock, C. A. (2023). Current Therapies in Kidney Transplant Rejection. Journal of Clinical Medicine, 12(15), 4927. https://doi.org/10.3390/jcm12154927
Vancouver
Alasfar S, Kodali L, Schinstock CA. Current Therapies in Kidney Transplant Rejection. Journal of Clinical Medicine. 2023;12(15):4927. doi:10.3390/jcm12154927
BibTeX
@article{Alasfar2023,
author = {Alasfar, Sami and Kodali, Lavanya and Schinstock, Carrie A},
title = {Current Therapies in Kidney Transplant Rejection},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {15},
pages = {4927},
doi = {10.3390/jcm12154927}
}
EUVIMED